Suppr超能文献

重症新型冠状病毒肺炎患者糖皮质激素的个体化应用:一篇叙述性综述

Tailoring glucocorticoids in patients with severe COVID-19: a narrative review.

作者信息

Luo Ming-Hao, Qian Yi-Qi, Huang Dan-Lei, Luo Jing-Chao, Su Ying, Wang Huan, Yu Shen-Ji, Liu Kai, Tu Guo-Wei, Luo Zhe

机构信息

Shanghai Medical College, Fudan University, Shanghai, China.

Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

出版信息

Ann Transl Med. 2021 Aug;9(15):1261. doi: 10.21037/atm-21-1783.

Abstract

OBJECTIVE

To discuss the pathogenesis of severe coronavirus disease 2019 (COVID-19) infection and the pharmacological effects of glucocorticoids (GCs) toward this infection. To review randomized controlled trials (RCTs) using GCs to treat patients with severe COVID-19, and investigate whether GC timing, dosage, or duration affect clinical outcomes. Finally. to discuss the use of biological markers, respiratory parameters, and radiological evidence to select patients for improved GC therapeutic precision.

BACKGROUND

COVID-19 has become an unprecedented global challenge. As GCs have been used as key immunomodulators to treat inflammation-related diseases, they may play key roles in limiting disease progression by modulating immune responses, cytokine production, and endothelial function in patients with severe COVID-19, who often experience excessive cytokine production and endothelial and renin-angiotensin system (RAS) dysfunction. Current clinical trials have partially proven this efficacy, but GC timing, dosage, and duration vary greatly, with no unifying consensus, thereby creating confusion.

METHODS

Publications through March 2021 were retrieved from the Web of Science and PubMed. Results from cited references in published articles were also included.

CONCLUSIONS

GCs play key roles in treating severe COVID-19 infections. Pharmacologically, GCs could modulate immune cells, reduce cytokine and chemokine, and improve endothelial functions in patients with severe COVID-19. Benefits of GCs have been observed in multiple clinical trials, but the timing, dosage and duration vary across studies. Tapering as an option is not widely accepted. However, early initiation of treatment, a tailored dosage with appropriate tapering may be of particular importance, but evidence is inconclusive and more investigations are needed. Biological markers, respiratory parameters, and radiological evidence could also help select patients for specific tailored treatments.

摘要

目的

探讨2019年冠状病毒病(COVID-19)重症感染的发病机制以及糖皮质激素(GCs)对该感染的药理作用。回顾使用GCs治疗重症COVID-19患者的随机对照试验(RCTs),并研究GCs的使用时机、剂量或疗程是否会影响临床结局。最后,讨论如何利用生物标志物、呼吸参数和影像学证据来选择患者,以提高GCs治疗的精准度。

背景

COVID-19已成为前所未有的全球挑战。由于GCs已被用作治疗炎症相关疾病的关键免疫调节剂,它们可能在限制重症COVID-19患者的疾病进展中发挥关键作用,这些患者常出现细胞因子过度产生以及内皮和肾素-血管紧张素系统(RAS)功能障碍,而GCs可通过调节免疫反应、细胞因子产生和内皮功能来发挥作用。目前的临床试验已部分证明了这种疗效,但GCs的使用时机、剂量和疗程差异很大,尚无统一共识,从而造成了混乱。

方法

检索截至2021年3月在科学网和PubMed上发表的文献。已发表文章中引用参考文献的结果也被纳入。

结论

GCs在治疗重症COVID-19感染中起关键作用。从药理学角度来看,GCs可调节免疫细胞,减少细胞因子和趋化因子,并改善重症COVID-19患者的内皮功能。多项临床试验已观察到GCs的益处,但不同研究中的使用时机、剂量和疗程各不相同。逐渐减量作为一种选择并未被广泛接受。然而,早期开始治疗、根据具体情况调整剂量并适当逐渐减量可能尤为重要,但证据尚无定论,还需要更多研究。生物标志物、呼吸参数和影像学证据也有助于选择适合特定个体化治疗的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad24/8421952/af086867a310/atm-09-15-1261-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验